Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Vertex Pharmaceuticals
Vertex Pharmaceuticals
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
Kalydeco
infants
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Motley Fool
Vertex Pharmaceuticals
exa-cel
beta thalassemia
sickle cell disease
Flag link:
Gene Editing Therapeutics Could Hit the Market in 2023
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Flag link:
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Yahoo/Businesswire
Vertex Pharmaceuticals
CRISPR Therapeutics
sickle cell disease
beta thalassemia
FDA
exa-cel
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Endpoints
Vertex Pharmaceuticals
diabetes
CRISPR
gene editing
CRISPR Therapeutics
Flag link:
Vertex flexes its dealmaking muscle
Vertex flexes its dealmaking muscle
EP Vantage
Vertex Pharmaceuticals
Entrada Therapeutics
Tevard Biosciences
Duchenne Muscular Dystrophy
Flag link:
Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic
Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic
Fierce Biotech
Vertex Pharmaceuticals
type 1 diabetes
cell therapy
VX-264
Flag link:
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Fierce Biotech
Vertex Pharmaceuticals
Immunogen
gen editing
antibody-drug conjugate
exa-cel
Flag link:
Vertex tiptoes further into Duchenne research with Tevard deal
Vertex tiptoes further into Duchenne research with Tevard deal
BioPharma Dive
Vertex Pharmaceuticals
Duchenne Muscular Dystrophy
DMD
Tevard Biosciences
Flag link:
Spotlight – Cystic fibrosis developers take a deep breath
Spotlight – Cystic fibrosis developers take a deep breath
EP Vantage
cystic fibrosis
MRNA
Vertex Pharmaceuticals
4D Molecular Therapeutics
Arcturus Therapeutics
Arrowhead Pharmaceuticals
Boehringer Ingelheim
Eloxx Pharmaceuticals
Krystal Biotech
Moderna Therapeutics
Oxford BioMedica
ReCode Therapeutics
SpliSense
Sumitomo Pharmaceuticals
Tessera Therapeutics
Flag link:
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
BioPharma Dive
Medicaid
sickle cell disease
gene therapies
Bluebird Bio
Vertex Pharmaceuticals
CRISPR Therapeutics
Flag link:
‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs
‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs
Stat
Vertex Pharmaceuticals
drug pricing
cystic fibrosis
patients
Flag link:
Vertex Teases Launch of Landmark CRISPR Therapy
Vertex Teases Launch of Landmark CRISPR Therapy
BioSpace
Vertex Pharmaceuticals
exa-cel
sickle cell disease
CRISPR
Flag link:
Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics
Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics
Fierce Pharma
Vertex Pharmaceuticals
drug pricing
activists
Trikafta
cystic fibrosis
Flag link:
Led by Merck, Vertex and Lilly, pharma's share prices largely climbed in '22 despite economic angst
Led by Merck, Vertex and Lilly, pharma's share prices largely climbed in '22 despite economic angst
Fierce Pharma
Merck
Vertex Pharmaceuticals
Eli Lilly
pharma stocks
Flag link:
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
EMA
CRISPR
sickle cell disease
exa-cel
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »